文献速递消化道肿瘤与早癌肝病

香港肝癌分期系统在接受动脉内治疗的北美患者预后判断中的验证

Validation of the Hong Kong Liver Cancer Staging System in Determining Prognosis of the North American Patients Following Intra-arterial Therapy.
PubMed 文献 · Clin Gastroenterol Hepatol · 2016-11-12

该研究回顾性分析了2000年至2014年间接受动脉内治疗的1009例肝细胞癌患者,比较香港肝癌分期系统(HKLC-5与HKLC-9)与巴塞罗那临床肝癌分期系统(BCLC)的预后预测效能。结果显示HKLC-5在生存区分度、校准度和判别力方面综合表现最佳,且持续优于BCLC系统;HKLC系统可识别出 unlikely 从动脉内治疗中获益的IV期和V期患者。

要点

  • HKLC-5预测生存的C统计量为0.71,优于BCLC的0.64。
  • HKLC-5和HKLC-9均显示良好的校准度。
  • HKLC系统识别的IV期和V期患者中,分别仅有小部分存活至6个月和4个月。

核心结论

  • 在因不可切除肝细胞癌接受动脉内治疗的患者回顾性分析中,HKLC-5分期系统在生存区分、校准和判别方面综合表现最佳,预测生存时间时持续优于BCLC系统。
  • HKLC系统可识别出 unlikely 从动脉内治疗中获益的IV期和V期肝细胞癌患者。

研究设计与样本

  • 回顾性分析2000年至2014年间接受动脉内治疗的1009例肝细胞癌患者,多数患者有丙型肝炎或肿瘤不可切除,所有患者均接受动脉内治疗,伴或不伴切除、移植和/或全身化疗。
  • 采用5级HKLC(HKLC-5)、9级HKLC(HKLC-9)和BCLC系统对每例患者进行分期,生存信息收集至2014年底,存活或未确认患者按删失处理。
  • 使用Kaplan-Meier估计、校准图、C统计量、Akaike信息准则和似然比检验比较BCLC、HKLC-5和HKLC-9系统的预测效能。

主要发现

  • 整个队列(所有分期)从首次动脉内治疗至死亡或删失的中位总生存时间为9.8个月。
  • BCLC和HKLC分期系统均能显著预测患者生存时间(P < .001)。
  • HKLC-5和HKLC-9均显示良好的校准度。
  • HKLC-5预测患者生存时间优于BCLC系统(HKLC C = 0.71,Akaike信息准则 = 6242;BCLC C = 0.64,Akaike信息准则 = 6320),降低预测生存时间的误差(HKLC降低误差14%,BCLC降低误差12%),同质性(HKLC卡方 = 201,P < .001;BCLC卡方 = 119,P < .001)和单调性(HKLC线性趋势卡方 = 193,P < .001;BCLC线性趋势卡方 = 111,P < .001)亦优于BCLC。
  • 根据HKLC系统,IV期和V期肝细胞癌患者中分别有小部分存活至6个月和4个月。

关键数值与推荐

  • HKLC-5预测生存的C统计量为0.71,Akaike信息准则为6242;BCLC的C统计量为0.64,Akaike信息准则为6320。
  • HKLC-5降低预测生存时间的误差为14%,BCLC降低误差为12%。
  • HKLC-5同质性卡方 = 201(P < .001),BCLC同质性卡方 = 119(P < .001)。
  • HKLC-5单调性线性趋势卡方 = 193(P < .001),BCLC线性趋势卡方 = 111(P < .001)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: There is debate over the best way to stage hepatocellular carcinoma (HCC). We attempted to validate the prognostic and clinical utility of the recently developed Hong Kong Liver Cancer (HKLC) staging system, a hepatitis B-based model, and compared data with that from the Barcelona Clinic Liver Cancer (BCLC) staging system in a North American population that underwent intra-arterial therapy (IAT). METHODS: We performed a retrospective analysis of data from 1009 patients with HCC who underwent IAT from 2000 through 2014. Most patients had hepatitis C or unresectable tumors; all patients underwent IAT, with or without resection, transplantation, and/or systemic chemotherapy. We calculated HCC stage for each patient using 5-stage HKLC (HKLC-5) and 9-stage HKLC (HKLC-9) system classifications, and the BCLC system. Survival information was collected up until the end of 2014 at which point living or unconfirmed patients were censored. We compared performance of the BCLC, HKLC-5, and HKLC-9 systems in predicting patient outcomes using Kaplan-Meier estimates, calibration plots, C statistic, Akaike information criterion, and the likelihood ratio test. RESULTS: Median overall survival time, calculated from first IAT until date of death or censorship, for the entire cohort (all stages) was 9.8 months. The BCLC and HKLC staging systems predicted patient survival times with significance (P < .001). HKLC-5 and HKLC-9 each demonstrated good calibration. The HKLC-5 system outperformed the BCLC system in predicting patient survival times (HKLC C = 0.71, Akaike information criterion = 6242; BCLC C = 0.64, Akaike information criterion = 6320), reducing error in predicting survival time (HKLC reduced error by 14%, BCLC reduced error by 12%), and homogeneity (HKLC chi-square = 201, P < .001; BCLC chi-square = 119, P < .001) and monotonicity (HKLC linear trend chi-square = 193, P < .001; BCLC linear trend chi-square = 111, P < .001). Small proportions of patients with HCC of stages IV or V, according to the HKLC system, survived for 6 months and 4 months, respectively. CONCLUSIONS: In a retrospective analysis of patients who underwent IAT for unresectable HCC, we found the HKLC-5 staging system to have the best combination of performances in survival separation, calibration, and discrimination; it consistently outperformed the BCLC system in predicting survival times of patients. The HKLC system identified patients with HCC of stages IV and V who are unlikely to benefit from IAT.

来源:Clin Gastroenterol Hepatol,查看原文。版权归原作者所有。

引用

  1. Sohn JH, Duran R, Zhao Y, et al. Validation of the Hong Kong Liver Cancer Staging System in Determining Prognosis of the North American Patients Following Intra-arterial Therapy. Clin Gastroenterol Hepatol. 2016. PMID: 27847278. doi:10.1016/j.cgh.2016.10.036

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。